Shu Lin

Program: Cancer Biology

Current advisor: Stephen Oh, MD, PhD

Undergraduate university: Vanderbilt University, 2022

Enrollment year: 2023

Research summary
LGALS1 as a target in MPN

We are targeting LGALS1 or galectin-1 as a novel therapeutic target in the treatment of myeloproliferative neoplasm (MPN)

Graduate publications
Kong T, Laranjeira ABA, Letson CT, Yu L, Lin S, Fowles JS, Fisher DAC, Ng S, Yang W, He F, Youn M, Mark K, Jose AS, Liu J, Kim AB, Cox MJ, Fulbright MC, Jayanthan A, Los G, Rentschler SL, Ding L, Sakamoto KM, Dunn SE, Challen GA, Oh ST. 2025 RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun, 16(1):492. PMCID: PMC11739599

Lin S, Li YE, Wang Y. 2025 Multi-Cohort Analysis Reveals Genetic Predispositions to Clonal Hematopoiesis as Mutation-Specific Risk Factors for Stroke. Adv Genet, 6(1):2400047. PMCID: PMC11909397

He F, Lin S, Gao B, Ramesh V, Kim AB, Kong T, Fisher DAC, Letson CT, Brakhane M, Fulbright M, Yu Y, Sardiello M, Di Paola J, Sykes SM, Oh ST. 2025 A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies. Cell Commun Signal, ():Online ahead of print. PMCID:

He F, Laranjeira AB, Kong T, Lin S, Ashworth KJ, Liu A, Lasky NM, Fisher DA, Cox MJ, Fulbright MC, Antunes-Heck L, Yu L, Brakhane M, Gao B, Sykes SM, D’Alessandro A, Di Paola J, Oh ST. 2024 Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. J Clin Invest, 343(3):e172256. PMCID: PMC10836808